BridgeBio Pharma, Inc.’s acoramidis found redemption, with the Phase III ATTRibute-CM showing positive results in transthyretin amyloid cardiomyopathy (ATTR-CM) as compared with the negative results at an interim analysis at the end of 2021. The positive Phase III data should carry the drug through to regulatory approval, but it may face commercial headwinds due to the entrenched position of Pfizer Inc.’s Vyndaqel/Vyndamax (tafamidis) franchise.
BridgeBio announced the ATTRibute-CM results on 17 July, stating that the study met its primary endpoint – consisting of a hierarchical analysis of all-cause mortality, frequency of cardiovascular-related hospitalization, change from baseline in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
